{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:21:14Z","timestamp":1780435274291,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["205687"],"award-info":[{"award-number":["205687"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.anai.2025.06.018","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T11:44:27Z","timestamp":1750333467000},"page":"336-338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Categorizing clinical response to mepolizumab for patients with chronic rhinosinusitis with nasal polyps: SYNAPSE trial"],"prefix":"10.1016","volume":"135","author":[{"given":"Claire","family":"Hopkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Borish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Dsilva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.anai.2025.06.018_bib0001","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.anai.2025.06.018_bib0002","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4193\/Rhin20.601","article-title":"Executive summary of EPOS 2020 including integrated care pathways","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"issue":"3","key":"10.1016\/j.anai.2025.06.018_bib0003","first-page":"287","article-title":"EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP","volume":"62","author":"Fokkens","year":"2024","journal-title":"Rhinology"},{"issue":"2","key":"10.1016\/j.anai.2025.06.018_bib0004","first-page":"144","article-title":"The relationship between subjective assessment instruments in chronic rhinosinusitis","volume":"45","author":"Lim","year":"2007","journal-title":"Rhinology"},{"issue":"2","key":"10.1016\/j.anai.2025.06.018_bib0005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4193\/Rhino15.072","article-title":"Stratification of SNOT-22 scores into mild, moderate or severe and relationship with other subjective instruments","volume":"54","author":"Toma","year":"2016","journal-title":"Rhinology"},{"issue":"5","key":"10.1016\/j.anai.2025.06.018_bib0006","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/lary.29766","article-title":"Development of sinonasal outcome test (SNOT-22) domains in chronic rhinosinusitis with nasal polyps","volume":"132","author":"Khan","year":"2022","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.anai.2025.06.018_bib0007","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/alr.22888","article-title":"The predictive utility of the 22-item sino-nasal outcome test (SNOT-22): A scoping review","volume":"12","author":"Liu","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"issue":"5","key":"10.1016\/j.anai.2025.06.018_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250647","article-title":"Mobile-phone-based e-diary derived patient reported outcomes: association with clinical disease activity, psychological status and quality of life of patients with multiple sclerosis","volume":"16","author":"Golan","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.anai.2025.06.018_bib0009","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s40629-016-0006-7","volume":"26","author":"Klimek","year":"2017","journal-title":"Allergo J Int"},{"issue":"3","key":"10.1016\/j.anai.2025.06.018_bib0010","first-page":"316","article-title":"Effect of biological treatment in uncontrolled severe chronic rhinosinusitis with nasal polyps in Belgium: a multicentre real-world data study","volume":"63","author":"Viskens","year":"2025","journal-title":"Rhinology"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625003102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625003102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:35:18Z","timestamp":1762364118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120625003102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1081120625003102"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.06.018","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Categorizing clinical response to mepolizumab for patients with chronic rhinosinusitis with nasal polyps: SYNAPSE trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}